Format

Send to

Choose Destination
Pharmacogenomics J. 2012 Jun;12(3):205-13. doi: 10.1038/tpj.2011.15. Epub 2011 Apr 19.

Economic impact of a genetic test for cisplatin-induced ototoxicity.

Author information

1
Centre for Clinical Epidemiology and Evaluation, VCHRI, Vancouver, Canada.

Erratum in

  • Pharmacogenomics J. 2012 Aug;12(4):359.

Abstract

Cisplatin is a widely used chemotherapy drug in the treatment of pediatric solid tumors, but it is associated with significant rates of ototoxicity (medication-induced hearing loss). A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. This study estimates the potential economic impact of this test. Assuming that an alternative, non-preferred, medication to cisplatin exists that it is as efficacious as cisplatin but without the risk of hearing loss, and that the alternative treatment is no more expensive than current practice, we have estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71,168 in societal costs per tested patient. This translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.

PMID:
21502965
DOI:
10.1038/tpj.2011.15
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center